← ANALYST RATINGS · TIPRANKS

Collegium Pharmaceutical (COLL): analyst forecast and price target

$23.19 0.04% close 16.10.26 · market cap $733M · Healthcare · Drug Manufacturers - Specialty & Generic IWM 0.03%
Price targets and ratings of

Analyst consensus

Moderate Buy

2 Buy1 Hold0 Sell

Ratings of 3 analysts in the last 3 months · top analysts only

12-month forecast

$46.33+99.8% upside

Based on 3 price targets given in the last 3 months, the average target is $46.33, the highest $50.00, the lowest $43.00. The average is +99.8% from the last price of $23.19.

$20.00$30.00$40.00$50.00Jan 26AprJulOctJan 27AprJulOctHigh$50.00Average$46.33Low$43.00
Highest target $50.00 Average target $46.33 Lowest target $43.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Jenna Davidner★★★★★★★★★★#10265 · hits 25% · avg −5.3% Barclays $48.00 Buy +107.0% Reiterated 15.10.26on TipRanks 05:07 +2.7%next day +1.1%
Les Sulewski★★★★★★★★★★#1947 · hits 51% · avg +11.5% Truist Financial $50.00 Buy +115.6% Reiterated 09.10.26on TipRanks Oct 12 05:50 −0.7%next day −0.1% · 5 days +6.9%
Les Sulewski★★★★★★★★★★#1947 · hits 51% · avg +11.5% Truist Financial $50.00 Buy +115.6% Initiated 23.09.26on TipRanks Sep 25 00:05 −0.7%next day +0.9% · 5 days −2.1%
Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% H.C. Wainwright $60.00 Buy +158.7% Reiterated 21.09.26on TipRanks 13:55 −0.4%next day −1.1% · 5 days −0.8%
Daniel Clark★★★★★★★★★★#3492 · hits 65% · avg +17.4% Leerink Partners $45.00 Buy +94.0% Initiated 09.09.26on TipRanks 08:25 +0.4%next day −1.3% · 5 days −3.9%
Name not given — $58.00 → $49.00−15.5% Buy +111.3% Initiated 09.09.26on TipRanks 07:08 +0.4%next day −1.3% · 5 days −3.9%
Jenna Davidner★★★★★★★★★★#10265 · hits 25% · avg −5.3% Barclays $56.00 → $48.00−14.3% Buy +107.0% Reiterated 18.08.26on TipRanks Aug 19 03:11 +2.2%next day +0.6% · 5 days −3.4%
David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% Piper Sandler $45.00 → $43.00−4.4% Hold +85.4% Reiterated 07.08.26on TipRanks 08:01 +0.6%next day −7.7% · 5 days −4.6%
Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% Needham $56.00 → $46.00−17.9% Buy +98.4% Reiterated 06.08.26on TipRanks 14:10 −18.4%next day +0.6% · 5 days −4.5%
Unknown Analyst Jefferies $51.00 Buy +119.9% Reiterated 20.03.26on TipRanks 14:42 −0.9%next day −3.0% · 5 days −6.2%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Collegium Pharmaceutical

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Les Sulewski★★★★★★★★★★Truist Financial · #1947
Hits 51%65 of 128 Average return +11.5%
1 year Serge Belanger★★★★★★★★★★Needham · #674
Hits 49%244 of 503 Average return +14.9%
2 years Brandon Folkes★★★★★★★★★★H.C. Wainwright · #10500
Hits 39%169 of 429 Average return −1.1%

Most profitable

3 months Les Sulewski★★★★★★★★★★Truist Financial · #1947
Hits 51%65 of 128 Average return +11.5%
1 year Serge Belanger★★★★★★★★★★Needham · #674
Hits 49%244 of 503 Average return +14.9%
2 years Brandon Folkes★★★★★★★★★★H.C. Wainwright · #10500
Hits 39%169 of 429 Average return −1.1%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $48.71 at a price of $21.82 (+123.3%); now: $48.71 at $23.19 (+110.1%).

$20.00$30.00$40.00$50.00Sep 15Oct 1Oct 15Top analysts$46.33Average target$48.71Price$23.19

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

02571031Oct 253Nov3Dec4Jan 265Feb251Mar333Apr433May232Jun13Jul11Aug21Sep31Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy421123
Buy333000
Hold320111
Sell000000

Earnings and sales forecast

Next report: 05.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $1.86 (from $1.72 to $1.97). Last quarter: $1.92.

Sales

Next quarter’s sales estimate — $216M (from $214M to $221M). Last quarter: $200M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.

Data from the stock’s TipRanks forecast page, read 37 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗